Oxford Genetics Secures £7.5 Million Investment

Industry Reports

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery,has announced a £7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual.

This investment will fund a new office in Boston, US and a 6,000-sq. ft. extension of its UK facility at the Oxford Science Park by November 2017. The extension will include state-of-the-art cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems and process development facilities. 

The company also plans to invest in its research and development capabilities to increase its intellectual property (IP) portfolio and support the growth of its of technology-enabled licensing business.

Ryan Cawood, CEO of Oxford Genetics, said: “The future is looking genuinely exciting for Oxford Genetics. Over the last few years there has been a huge number of promising steps in the complex biologics field towards delivering real patient benefits and Oxford Genetics is pleased to be working with so many of the companies tackling some of medicines most significant challenges. This latest investment will allow us to further strengthen our solid foundations of innovative technologies and operational excellence and deliver on our mission to improve the overall efficiency of the biotherapeutic industry through the application of synthetic biology.” 

The announcement follows a successful year for Oxford Genetics with a rapidly increasing number of clients, key appointments, and market momentum in the growth areas of cell and gene therapy. It has also signed a number of licenses for use of its technologies, including two collaborative partnerships with gene therapy companies designed to develop its IP offering further, as well as filing five new patents intended to improve the discovery, development or delivery of biotherapeutics. 

Matthew Mead, chief investment officer at Mercia said: “Our latest investment into Oxford Genetics reflects its rapid growth as the business continues to grow and expand into the US market. Since first investing in Oxford Genetics via our third party managed funds in 2013 and then transferring it to Mercia's direct investment portfolio of 'Emerging Stars' in December 2015, we have seen the business continue to accelerate its commercial progress, in what is proving to be a very attractive sector and growing market.” 

The investment into Oxford Genetics’ offering is exceptionally well-timed with the rapidly increasing demand for solutions that improve the discovery and development of biotherapeutics driving the need for expert technology providers to support and scale companies’ research efforts. 

About Oxford Genetics
Oxford Genetics, headquarted in Oxford, UK, is a leading synthetic biology company dedicated to the creation of biology-based technologies to aid in the discovery and development of biologics, cell and gene therapies. Founded in 2011, the company has experience in DNA design for the optimisation of protein expression, improved viral delivery systems and cell line engineering.

Sign up via our free email subscription service to receive notifications when new information is available.

Market Movers

Rogers Corporation

NYQ : ROG - 19 Sep, 2:30pm
+0.3886 (+0.3048%) After Hours:
Open 128.0000 Mktcap 2.32B
High 128.0000 52wk Hight 128.0000
Low 127.0300 52wk Low 51.9800
Vol 26544 Avg Vol 120339
Eps 5.5500 P/e 30.8388
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 19 Sep, 2:31pm
+0.085 (+1.267%) After Hours:
Open 6.780 Mktcap 104.51B
High 6.800 52wk Hight 6.990
Low 6.760 52wk Low 4.190
Vol 3.66M Avg Vol 5.46M
Eps 0.490 P/e 12.560
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 19 Sep, 2:32pm
-0.07 (-0.11%) After Hours:
Open 66.02 Mktcap 179.79B
High 66.16 52wk Hight 66.80
Low 65.68 52wk Low 58.29
Vol 3.10M Avg Vol 8.07M
Eps 3.87 P/e 35.69
Currency: USD

Johnson & Johnson

NYQ : JNJ - 19 Sep, 2:32pm
-0.08 (-0.06%) After Hours:
Open 135.02 Mktcap 363.15B
High 135.79 52wk Hight 137.08
Low 134.35 52wk Low 109.32
Vol 2.59M Avg Vol 5.39M
Eps 7.18 P/e 22.89
Currency: USD

Pfizer, Inc.

NYQ : PFE - 19 Sep, 2:32pm
-0.05 (-0.14%) After Hours:
Open 35.66 Mktcap 211.13B
High 35.66 52wk Hight 35.84
Low 35.35 52wk Low 29.83
Vol 7.99M Avg Vol 17.45M
Eps 2.56 P/e 25.97
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 19 Sep, 12:59pm
+0.06 (+0.48%) After Hours:
Open 13.71 Mktcap
High 13.71 52wk Hight 16.29
Low 13.71 52wk Low 12.79
Vol 277 Avg Vol 4720
Eps P/e
Currency: USD